MS Phase 2 Study ACT-128800 Report for Patients Like You

Filter by:

All
Start typing to see suggestions

patients

Home > Community Treatment Reports and Side Effects > MS Phase 2 Study ACT-128800 Treatment Report

You appear to have JavaScript disabled in your browser. PatientsLikeMe relies on JavaScript and Cookies to deliver the best possible experience to you. How do I enable JavaScript?

What is MS Phase 2 Study ACT-128800?

NCT01006265 is a randomized, double-blind, placebo-controlled, parallel-group, dose-finding study to evaluate the efficacy, safety, and tolerability of 3 doses of ACT-128800 administered for 24 weeks in patients with relapsing-remitting multiple sclerosis. Other study name is AC-058B201.

Reported Purpose & Efficacy

Reasons and Efficacy
Purpose	# of patients	# of patients with evaluations Efficacy	Major	Moderate	Slight	None	Can’t tell
Participate in clinical trial	1	0
Cognitive Confusion	1	0
Walking problems	1	0

See 1 patient currently using MS Phase 2 Study ACT-128800

Mouse over the table for more information

Reported Schedules

	1 other daily
	1

Reported Duration See details about how long patients take this treatment ▼ Reported Duration Hide details ▲

Currently Using MS Phase 2 Study ACT-128800

A bar graph

0-1 month	1-3 months	3-6 months	6 months-1year	1-2 years	2 years or more
0	0	0	0	1	0

Report created on May 26, 2012.